Cumberland Pharmaceuticals Inc (NASDAQ: CPIX), a United States-based specialty pharmaceutical company, has started a national initiative to support the treatment of patients with hospital-acquired and ventilator-associated pneumonia, following the outbreak of COVID-19, it was reported on Monday.

The company produces the potent antibiotic VIBATIV (telavancin) injection, intended to treat serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA).

The company's initiative includes the availability of special financial arrangements for hospitals and clinics to help ensure supply during this unprecedented healthcare crisis. The company is also sponsoring a national program with infectious disease experts to offer information on the management of complicated respiratory infections resulting from the novel coronavirus. The special financial arrangements being offered by company include extended payment terms for all direct account purchases of its VIBATIV antibiotic.